My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

58.52 +0.02 (+0.04%)

Streaming Delayed Price Updated: 11:47 AM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

44 45 Next >

Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review ↗

February 02, 2024

The Dow led the major indexes higher. Big techs diverged on results.

Via Investor's Business Daily

Topics Economy Stocks

What's Going On With GSK Stock Today? ↗

February 01, 2024

GSK settles U.S. Zantac lawsuit, avoiding trial. Confidential settlements reinforce commitment to legal efficiency.

Via Benzinga

Topics Lawsuit

Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections ↗

January 31, 2024

Teva Pharmaceutical easily beat fourth-quarter views, but its 2024 profit guidance left something to be desired.

Via Investor's Business Daily

GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine Shine ↗

January 31, 2024

GSK's robust Q4 performance with a 21% YoY increase in adjusted operating profit. Arexvy vaccine sales hit £1.2B in 2023. Outlook for 2024, with 5%-7% sales growth and upgraded long-term projections.

Via Benzinga

Recap: GSK Q4 Earnings ↗

January 31, 2024

Via Benzinga

Earnings Outlook For GSK ↗

January 30, 2024

Via Benzinga

A Look Into GSK Inc's Price Over Earnings ↗

January 26, 2024

Via Benzinga

Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser ↗

January 31, 2024

The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.

Via Benzinga

Topics Economy

Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60% ↗

January 30, 2024

Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.

Via Benzinga

Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology

January 24, 2024

From Elegen

Via Business Wire

What the Options Market Tells Us About GSK ↗

January 09, 2024

Via Benzinga

Earnings Scheduled For January 31, 2024 ↗

January 31, 2024

Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.

Via Benzinga

Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? ↗

January 29, 2024

An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.

Via Benzinga

Topics Artificial Intelligence

GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M ↗

January 17, 2024

GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake.

Via Benzinga

Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week ↗

January 13, 2024

Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...

Via Talk Markets

Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles ↗

January 09, 2024

Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning

Via Benzinga

GSK Boosts Its Asthma Product Portfolio With Over $1B Deal For Aiolos Bio ↗

January 09, 2024

GSK plc (NYSE: GSK) has agreed to acquire Aiolos Bio Inc

Via Benzinga

GSK Enters Agreement to Acquire Aiolos Bio

January 09, 2024

From Aiolos Bio, Inc.

Via Business Wire

GlaxoSmithKline PLC (NYSE: GSK) Records 52-Week High Monday Morning

January 08, 2024

Via Investor Brand Network

Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada ↗

January 05, 2024

The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.

Via Benzinga

Why Biopharmaceutical Player CureVac Shares Are Rising Today ↗

January 05, 2024

CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday.

Via Benzinga

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Sleeper Hits: 3 Unexpected Stocks Poised for a Breakout in 2024 ↗

January 05, 2024

Many stocks emerge from Wall Street's doghouse relatively quickly. Here are three names that could become surprise breakout stocks for 2024.

Via InvestorPlace

More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024 ↗

January 04, 2024

More than 140 brands of drugs are going to see their prices hiked heading into the new year

Via Talk Markets

Dell To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

January 03, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves ↗

December 29, 2023

In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion...

Via Benzinga

Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January ↗

December 29, 2023

Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...

Via Benzinga

Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024 ↗

December 28, 2023

2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.

Via Benzinga

3 Growth at a Reasonable Price (GARP) Stocks for Balanced Growth ↗

December 22, 2023

GARP stocks are less likely to plunge than growth stocks with high valuations and more likely to generate strong growth than value stocks.

Via InvestorPlace

Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection ↗

December 21, 2023

The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or...

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition